Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
VANCOUVER BIOTECH LTD. currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single matter is handled by 1 distinct examiner, showing a highly focused point of interaction at the USPTO. The prosecution is situated within 1 distinct art unit, indicating that the company's current technical focus is concentrated within a specific area of biotechnology.
The busiest examiner for the company is PUTTLITZ, KARL J, who is overseeing 1 busiest examiner pending action. This accounts for the total number of pending office actions currently active for the portfolio. With only 1 distinct examiner involved, the company's immediate success is tied to the specific examination style of PUTTLITZ, KARL J. Practitioners should prioritize a direct and responsive strategy to address the 1 pending office action. The concentration within 1 distinct art unit further suggests that the company is pursuing a targeted intellectual property strategy. Navigating the requirements of the 1 distinct examiner will be the primary objective for the company's legal representatives.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PUTTLITZ, KARL J | 1 | 69.2% | +18.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18286895 | Applications of GHR-106 Monoclonal Antibody as a GnRH Antagonist | PUTTLITZ, KARL J | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18286895 | Applications of GHR-106 Monoclonal Antibody as a GnRH Antagonist | PUTTLITZ, KARL J | 1646 | §103DP | Final Rejection | — | Pending | Oct 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVANCOUVER BIOTECH LTD. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Karl J Puttlitz has the most, with 1 of VANCOUVER BIOTECH LTD.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
